TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 1529944
Drug: Treatment trial
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment trial
Study: 3981321
Drug: Preterm milk
Normalized name: MILK
DrugBank: Cow milk (DB10543)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preterm milk with iron supplementation (2 mg/kg/day)
Study: 3981321
Drug: Mature human
Normalized name: Immature human tripeptidyl-peptidase 1
DrugBank: Cerliponase alfa (DB13173)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Mature human milk with iron supplementation (2 mg/kg/day)
Study: 3981321
Drug: Infant formula
Normalized name: Infant formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infant formula with iron supplementation (2 mg/kg/day)
Study: 26902092
Drug: 50 g
Normalized name: glucose 50 g/296 mL oral liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 g of dried plum
Study: 26902092
Drug: 100 g
Normalized name: Berri-Freez 4.5 GM per 100 GM
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 g of dried plum
Study: 24525660
Drug: Tianeptine (37.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tianeptine (37.5 mg/d)
Study: 22463596
Drug: Good adherence
Normalized name: miconazole
DrugBank: Miconazole (DB01110)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Good adherence (never missed pills in the last month)
Study: 22463596
Drug: 100% Drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100% Drug Possession Ratio (DPR) throughout the first year
Study: 22463596
Drug: Poor adherence
Approvals — FDA: no, EMA: no, PMDA: no
Description: Poor adherence subgroup by Drug Possession Ratio (DPR)
Study: 16167789
Drug: PGE1 (0.05
Approvals — FDA: no, EMA: no, PMDA: no
Description: PGE1 (0.05 microg x kg(‐1) x min(‐1) administered intravenously during surgery)
Study: 16167789
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no PGE1 administration)
Study: 12800126
Drug: Nicotine-replacement therapy
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotine-replacement therapy and bupropion
Study: 10992178
Drug: Postoperative administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postoperative administration of low-dose cyclic oral contraceptives for 6 months
Study: 8833056
Drug: Combination treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination treatment (MTX 5/50-7.5/100 mg/week/day)
Study: 8833056
Drug: Azathioprine (AZA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azathioprine (AZA 50-150 mg/day)
Study: 8833056
Drug: Methotrexate (MTX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methotrexate (MTX 5-15 mg/week)
Study: 8833056
Drug: Combination treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination treatment and AZA
Study: 1459383
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no treatment for first 3 months)
Study: 23175563
Drug: DHP +
Normalized name: DHP ether
DrugBank: Dihematoporphyrin ether (DB15351)
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHP + primaquine (0.75 mg/kg single dose on day 3)
Study: 18433844
Drug: Simvastatin (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin (80 mg/day for 5 days)
Study: 18433844
Drug: Rosuvastatin (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosuvastatin (40 mg/day for 5 days)
Study: 14677161
Drug: Low level
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low level laser therapy (LLLT) + stretching exercises
Study: 1727902
Drug: Intravenous 2',3'-dideoxyinosine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous 2',3'-dideoxyinosine (ddI)
Study: 1727902
Drug: Oral 2',3'-dideoxyinosine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral 2',3'-dideoxyinosine (ddI)
Study: 6724661
Drug: High protein
Normalized name: Vital High Protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: High protein supplement (58 g/day of a 60:40 mixture of soy and wheat proteins)
Study: 6724661
Drug: Low protein
Normalized name: Low protein mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low protein supplement (7 g/day of rice protein)
Study: 26551600
Drug: Mother-infant psychoanalytic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mother-infant psychoanalytic treatment (MIP) group
Study: 19720342
Drug: Herbal drug
Normalized name: herbal drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Herbal drug (500 mg of saffron, celery seed, and anise extracts three times a day for three days)
Study: 8788323
Drug: Standard behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard behavioral treatment program (SBT)
Study: 7350310
Drug: Sucrose electrolyte
Normalized name: Sucrose
DrugBank: Sucrose (DB02772)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sucrose electrolyte oral solution
Study: 7350310
Drug: Glucose electrolyte
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose electrolyte oral solution
Study: 30755381
Drug: IA‐TXA (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: IA‐TXA (15 mg/kg)
Study: 30755381
Drug: IV‐TXA (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV‐TXA (10 mg/kg)
Study: 30755381
Drug: IA‐TXA (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: IA‐TXA (15 mg/kg) and IV‐TXA (10 mg/kg)
Study: 23582675
Drug: Intracoronary administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intracoronary administration of darbepoetin-alpha (DA) 150 μg
Study: 19207722
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg nicotine tablet
Study: 11370797
Drug: Losartan (50-100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan (50-100 mg/day) for 12 weeks
Study: 9198730
Drug: Dexfenfluramine (dF)
Normalized name: dexfenfluramine
DrugBank: Dexfenfluramine (DB01191)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexfenfluramine (dF) 15 mg bid
Study: 8458924
Drug: Oestradiol valerate
Normalized name: Estradiol Valerate
DrugBank: Estradiol valerate (DB13956)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oestradiol valerate 6 mg per os daily + intravaginal micronized progesterone 600 mg daily
Study: 8458924
Drug: Intravaginal micronized
Normalized name: Intravaginal contraceptives
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravaginal micronized progesterone 600 mg daily
Study: 3007984
Drug: Intravenous cytomegalovirus
Normalized name: cytomegalovirus immunoglobulin
DrugBank: Human cytomegalovirus immune globulin (DB13886)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous cytomegalovirus immune globulin and seronegative blood products
Study: 30590410
Drug: mAHTPred (meta-predictor
Approvals — FDA: no, EMA: no, PMDA: no
Description: mAHTPred (meta-predictor using ensemble learning of four ML algorithms)
Study: 22675968
Drug: Diclofenac sodium
Normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Diclofenac sodium suppositories (100 mg/day)
Study: 22675968
Drug: Indomethacin suppositories
Normalized name: Indomethacin Suppositories
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin suppositories (100 mg/day)
Study: 20099281
Drug: Lowest level
Normalized name: peanut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lowest level of methylation in LINE‐1 among CC carriers for the MTRR Ex5+123C>T polymorphism
Study: 17509235
Drug: Dapsone (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dapsone (200 mg single dose)
Study: 12060479
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy of tazarotene and mometasone furoate
Study: 12060479
Drug: All topical
Normalized name: Rexall Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: All topical therapy regimens
Study: 8789310
Drug: Quadruple therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quadruple therapy with omeprazole, bismuth, tetracycline and metronidazole for 1 week (pretreated with omeprazole for 3 days)
Study: 8789310
Drug: Dual therapy
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual therapy with omeprazole and amoxicillin for 2 weeks
Study: 1872398
Drug: Graded balloon
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Graded balloon distensions (1 min duration at 10-min intervals in 8-ml stepwise increments)
Study: 21332375
Drug: VR-graded exposure
Normalized name: Prostin VR
DrugBank: Alprostadil (DB00770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: VR-graded exposure therapy (VR-GET)
Study: 19178390
Drug: TTFC administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: TTFC administered in the evening
Study: 19178390
Drug: TTFC administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: TTFC administered in the morning
Study: 17578973
Drug: Extended-release epidural
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended-release epidural morphine (EREM) 10 mg
Study: 17578973
Drug: Conventional epidural
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional epidural morphine 4 mg
Study: 15190961
Drug: Dopamine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dopamine infusion at 2, 4, and 6 microg x kg(‐1) x min(‐1)
Study: 11464357
Drug: 10 mL
Normalized name: Vial Empty 10 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mL of 0.75% ropivacaine plus 0.5 mL of 0.9% NaCl (solution A)
Study: 11464357
Drug: 10 mL
Normalized name: Vial Empty 10 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mL of 0.75% ropivacaine plus 0.0012 mEq of NaHCO(3) (solution B)
Study: 11464357
Drug: 10 mL
Normalized name: Vial Empty 10 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mL of 0.75% ropivacaine (with adrenaline) plus 0.015 mEq of NaHCO(3) (solution C)
Study: 25808588
Drug: TNF-α inhibitors
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: TNF-α inhibitors (adalimumab, infliximab, etanercept, certolizumab pegol, golimumab)
Study: 18328151
Drug: Back school
Normalized name: Pep-Back
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Back school program (five-weekly sessions)
Study: 18328151
Drug: Weekly medical
Normalized name: elagolix
DrugBank: Elagolix (DB11979)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Weekly medical visits (control group)
Study: 16691029
Drug: Fluvastatin XL,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvastatin XL, 80 mg, morning administration
Study: 16691029
Drug: Fluvastatin XL,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvastatin XL, 80 mg, evening administration
Study: 8665116
Drug: Oral contraceptive
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral contraceptive (1 mg norethindrone and 35 micrograms ethinyl oestradiol) for 21 days, n = 7
Study: 1387301
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg oral tablet formulation 1
Study: 1387301
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg oral tablet formulation 2
Study: 1387301
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of the lactobionate salt
Study: 1387301
Drug: Oral dosing
Normalized name: oral dosing devices
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral dosing of clarithromycin
Study: 29284534
Drug: Perineural catheter
Normalized name: ropivacaine
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Perineural catheter (PNC) with continuous local anaesthetic infusion for the first 5 postoperative days
Study: 24330343
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg oxymorphone ER after a high-fat meal
Study: 24330343
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg oxymorphone ER after fasting
Study: 21117499
Drug: Test product
Normalized name: Patch test product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test product Lipivim (200 mg fenofibrate)
Study: 21117499
Drug: Reference product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference product (200 mg fenofibrate)
Study: 17212680
Drug: Diclofenac epolamine
Normalized name: Diclofenac Epolamine
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Diclofenac epolamine (DHEP) 65-mg sachet
Study: 781495
Drug: Prindolol (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prindolol (10 mg three times per day)
Study: 781495
Drug: Prindolol (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prindolol (10 mg three times per day) + Hydrochlorothiazide (50 mg per day)
Study: 21845501
Drug: Treatment A
Normalized name: Nix Ultra Lice Treatment And Prevention Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment A (gpc training for oral reading and spelling, orthographic spelling strategy, RAP training, morphological strategies)
Study: 21845501
Drug: Treatment B
Normalized name: PanOxyl Acne Treatment Bar
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment B (gpc training for oral reading and phonological awareness, continued step 2 training, orthographic spelling strategy training)
Study: 21845501
Drug: Treatment A
Normalized name: Nix Ultra Lice Treatment And Prevention Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment A (RAP training during step 3)
Study: 22123798
Drug: Internet-delivered intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Internet-delivered intervention (quarterly educational modules, practice guidelines, monthly literature summaries, automated e-mail reminders) for 27 months
Study: 17035947
Drug: Radiation therapy
Normalized name: Sensitizers used in photodynamic/radiation therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiation therapy (a single dose of 18.4 Gy)
Study: 12964797
Drug: ACE Surgical
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACE Surgical resorbable blast media (RBM) dental implant
Study: 10846695
Drug: 6 days
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 days of treatment with clarithromycin 500 mg, amoxicillin 1 g and omeprazole 20 mg, b.i.d.
Study: 10846695
Drug: 7 days
Normalized name: ZINGIBER OFFICINALE (GINGER) ROOT OIL 0.006 mg in 30 mg TOPICAL LIQUID [JAYSUING 7 Days Nail Fungus Treatment]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7 days of treatment with clarithromycin 500 mg, amoxicillin 1 g and omeprazole 20 mg, b.i.d.
Study: 9356566
Drug: Panic Disorder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Panic Disorder Severity Scale (after short-term treatment)
Study: 3769163
Drug: Amiodarone plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amiodarone plus type IA agent (group 2, 17 patients)
Study: 3769163
Drug: Procainamide (administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Procainamide (administered during amiodarone therapy)
Study: 30589027
Drug: Hypofractionated SIB-IMRT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypofractionated SIB-IMRT at 3.6 Gy/f (total of 72 Gy/20 fractions) combined with temozolomide (TMZ) at 75 mg/m2/day during radiotherapy and 150-200 mg/m2/day for 5 days every 28 days.
Study: 30589027
Drug: Hypofractionated SIB-IMRT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypofractionated SIB-IMRT at 4 Gy/f (considered dose-limiting toxicity)
Study: 26439785
Drug: CRE (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: CRE (5 g of CRE monohydrate, 4 times per day; n = 14)
Study: 26439785
Drug: CRE +
Normalized name: dimethicone
DrugBank: Dimethicone (DB11074)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CRE + CAF (CRE + 300 mg·d of CAF; n = 13)
Study: 26439785
Drug: CRE +
Normalized name: dimethicone
DrugBank: Dimethicone (DB11074)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CRE + COF (CRE + 8.9 g of COF, yielding 303 mg of CAF; n = 13)
Study: 23229691
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg intravitreal triamcinolone acetonide
Study: 23229691
Drug: Standard care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard care and triamcinolone treatments
Study: 15602501
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg oral D‐amphetamine
Study: 15602501
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg oral D‐amphetamine
Study: 23318559
Drug: Choline supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Choline supplementation (twice normal dietary levels)
Study: 18681892
Drug: Standard triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard triple eradication therapy + Saccharomyces boulardii (250 mg b.i.d. for 4 weeks)
Study: 18681892
Drug: Standard triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard triple eradication therapy (omeprazole/esomeprazole, amoxicillin and clarithromycin)
Study: 18681892
Drug: Standard triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard triple eradication therapy + Saccharomyces boulardii
Study: 18681892
Drug: Standard triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard triple eradication therapy
Study: 16626572
Drug: Standard drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard drug therapy and percutaneous coronary intervention (PCI)
Study: 9477031
Drug: Cognitive approach
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive approach treatment (n = 9)
Study: 9477031
Drug: Relaxation component
Normalized name: thrombin
DrugBank: Thrombin (DB11300)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Relaxation component treatment (n = 12)
Study: 3299568
Drug: Ambroxol (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ambroxol (10 mg/kg, i.v. twice daily for 7 days)
Study: 23291937
Drug: Individually tailored
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individually tailored educational web pages addressing specific vaccine concerns
Study: 14557454
Drug: GHRH antagonist
Normalized name: GHRH(1-44)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GHRH antagonist infusion
Study: 10805184
Drug: albendazole therapy
Normalized name: Albendazole
DrugBank: Albendazole (DB00518)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: albendazole therapy
Study: 8927671
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg fluoxetine weekly
Study: 7104182
Drug: Indomethacin retard
Normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Indomethacin retard 75 mg twice daily
Study: 7104182
Drug: Indomethacin capsules
Normalized name: Indomethacin Capsules
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Indomethacin capsules 50 mg three times daily
Study: 7104182
Drug: Indomethacin 100
Normalized name: indomethacin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin 100 mg suppository at night with 50 mg by mouth each morning
Study: 7104182
Drug: Indomethacin retard
Normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Indomethacin retard therapy
Study: 27180314
Drug: Ibogaine 20
Normalized name: ibopamine
DrugBank: Ibopamine (DB13316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibogaine 20 mg
Study: 22429766
Drug: Recent regular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recent regular aspirin use
Study: 22429766
Drug: Recent regular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recent regular ibuprofen use
Study: 9076841
Drug: Policosanol 10
Normalized name: policosanol 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Policosanol 10 mg day-1
Study: 9076841
Drug: Policosanol 20
Normalized name: POLICOSANOL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Policosanol 20 mg day-1
Study: 9076841
Drug: Policosanol 40
Normalized name: POLICOSANOL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Policosanol 40 mg day-1
Study: 1859490
Drug: Methotrexate (MTX)
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate (MTX) 7.5 mg weekly, increased based on clinical improvement
Study: 1859490
Drug: Azathioprine (AZA)
Normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Azathioprine (AZA) 100 mg daily, increased based on clinical improvement
Study: 31705307
Drug: artificial saliva
Normalized name: ARTIFICIAL SALIVA
Approvals — FDA: no, EMA: no, PMDA: no
Description: artificial saliva solution (negative control)
Study: 29352829
Drug: Multiple-micronutrient powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple-micronutrient powder (daily dose for 3 months)
Study: 24673045
Drug: Far-infrared therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Far-infrared therapy
Study: 12161488
Drug: One etonogestrel
Normalized name: Etonogestrel
DrugBank: Etonogestrel (DB00294)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: One etonogestrel implant
Study: 12161488
Drug: Two etonogestrel
Normalized name: Etonogestrel
DrugBank: Etonogestrel (DB00294)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Two etonogestrel implants
Study: 12161488
Drug: Control (baseline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (baseline testosterone treatment)
Study: 10198397
Drug: Granulocyte colony-stimulating
Normalized name: Granulocyte colony-stimulating factor lenograstim
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Granulocyte colony-stimulating factor (G-CSF, 300 microgram sc)
Study: 7762524
Drug: Rectal acetate
Normalized name: Rectal Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rectal acetate (12.5 mmol [1,2‐13C]sodium acetate)
Study: 7762524
Drug: Intravenous acetate
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous acetate (12.5 mmol [1,2‐13C]sodium acetate)
Study: 7762524
Drug: Rectal acetate
Normalized name: Rectal Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rectal acetate with propionate (6 mmol sodium propionate)
Study: 24846822
Drug: Hydromorphone ER
Normalized name: hydromorphone Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydromorphone ER (8-32 mg)
Study: 24846822
Drug: Oxycodone CR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxycodone CR (10-40 mg)
Study: 18931525
Drug: Hydrocortisone (HC)
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Hydrocortisone (HC) treatment for 10 days
Study: 18931525
Drug: Meta-analysis of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meta-analysis of hydrocortisone treatment
Study: 16134519
Drug: Transamin 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transamin 1.0 g i.v.